Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Assessment of Aggressive B-Cell Lymphoma Treatment Response and Prediction of Recurrence Using Phased Variant Analysis With Next-Generation Sequencing

NCT06550427 is registered in ClinicalTrials.gov with National Taiwan University Hospital as lead sponsor.

NCT NCT06550427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06550427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Assessment of Aggressive B-Cell Lymphoma Treatment Response and Prediction of Recurrence Using Phased Variant Analysis With Next-Generation Sequencing
Lead sponsor
National Taiwan University Hospital
Phase
Observational
Overall status
Recruiting
Start date
August 9, 2024
Completion date
July 31, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, lymphoma, t-cell lymphoma, waldenstrom macroglobulinaemia